This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Diphenhydramine and Sweating

Sponsored by Lakehead University

About this trial

Last updated 2 years ago

Study ID

2022509

Status

Completed

Type

Interventional

Phase

Phase 4

Placebo

Yes

Accepting

18-75 Years
18 to 49 Years
All
All

Trial Timing

Ended 2 years ago

What is this trial about?

In 2012, it was estimated that nearly 1 in 4 Canadians suffer from allergic rhinitis. To add, 78% of individuals working in predisposing environments are predicted to develop occupational rhinitis. Currently, the most popular treatment for rhinitis is antihistamine medication such as diphenhydramine, a first-generation antihistamine sold commercially as Benadryl®. Due it its anticholinergic effects, diphenhydramine has been suggested to impair the whole body sweating response during heat stress, potentially leaving consumers at an increased risk of heat-related illness. This randomized control trial approved by Health Canada will investigate whether ingesting extra strength diphenhydramine (50mg) will alter whole-body sweat losses during 60 minutes of exercise.

What are the participation requirements?

Yes

Inclusion Criteria

- Able to safely perform ~60 minutes of moderate intensity exercise

- No known hypersensitivity to diphenhydramine

- Not on any prescribed medication

- Body-mass index (BMI) less than 30

No

Exclusion Criteria

- Outside 18 - 49 years of age

- Diagnosed with any cardiovascular, respiratory, neurological or metabolic disease

- History of any cardiovascular, respiratory, neurological or metabolic disease

- Unable to exercise for 60 minutes at moderate intensity, or have a musculoskeletal injury

- BMI > or = 30

Locations

Location

Status